Insider Buying: OraSure Technologies, Inc. (NASDAQ:OSUR) CFO Buys $201,600.00 in Stock

OraSure Technologies, Inc. (NASDAQ:OSUR) CFO Kenneth J. Mcgrath bought 64,000 shares of OraSure Technologies stock in a transaction on Thursday, February 27th. The shares were purchased at an average cost of $3.15 per share, for a total transaction of $201,600.00. Following the acquisition, the chief financial officer now owns 371,013 shares in the company, valued at $1,168,690.95. The trade was a 20.85 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

OraSure Technologies Stock Performance

NASDAQ OSUR opened at $3.48 on Friday. OraSure Technologies, Inc. has a one year low of $2.68 and a one year high of $7.81. The company has a 50-day simple moving average of $3.78 and a 200-day simple moving average of $4.00. The firm has a market capitalization of $259.59 million, a PE ratio of 23.20 and a beta of 0.05.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, February 22nd.

Hedge Funds Weigh In On OraSure Technologies

A number of hedge funds and other institutional investors have recently bought and sold shares of OSUR. Creative Planning acquired a new stake in shares of OraSure Technologies during the 3rd quarter worth approximately $54,000. Assenagon Asset Management S.A. increased its position in OraSure Technologies by 25.7% in the third quarter. Assenagon Asset Management S.A. now owns 205,559 shares of the medical instruments supplier’s stock worth $878,000 after buying an additional 42,017 shares during the period. Ballentine Partners LLC acquired a new stake in OraSure Technologies in the third quarter worth $159,000. Principal Financial Group Inc. lifted its stake in OraSure Technologies by 28.1% in the third quarter. Principal Financial Group Inc. now owns 66,060 shares of the medical instruments supplier’s stock valued at $282,000 after buying an additional 14,480 shares during the last quarter. Finally, Empowered Funds LLC boosted its holdings in shares of OraSure Technologies by 22.6% during the third quarter. Empowered Funds LLC now owns 359,419 shares of the medical instruments supplier’s stock valued at $1,535,000 after acquiring an additional 66,210 shares during the period. 93.50% of the stock is currently owned by institutional investors and hedge funds.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.